相关实验视频

Updated: May 28, 2025

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

物理化疗基于酸盐的水凝通过抗氧化和抗炎作用抑制脂质生成,用于治疗肥胖症

Xiaochang Chen¹, Peihong Su¹, Hua Guan¹

¹Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China.

International journal of biological macromolecules

|February 9, 2025

概括

一种新的纳米复合材料水凝,SDAR,充满了白醇纳米颗粒,有效地打击肥胖. 这种光热疗法减少炎症并抑制脂肪细胞的发展,提供了一个有前途的新治疗策略.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
代谢性疾病研究研究

背景情况:

肥胖与高血压和胰岛素抵抗等严重健康问题有关,需要新的治疗方法.
物理化疗,结合化学和物理方法,显示出潜力,但需要进一步了解肥胖治疗的机制.
目前针对肥胖的治疗策略缺乏创新和有效性.

研究的目的:

开发和评估一个光热纳米复合物水凝 (SDAR) 装有复星纳米颗粒用于减轻肥胖.
研究SDAR抑制脂质发生和减少与肥胖相关的标记物的机制.
评估SDAR作为肥胖症物理化疗方法的治疗潜力.

主要方法:

使用聚多巴胺功能化藻酸盐,Zn2+和复星纳米颗粒合成的SDAR水凝.
复星纳米颗粒和SDAR水凝特性的表征,包括光热稳定性,生物相容性,抗氧化能力和抗炎作用.
在使用3T3-L1预adipocytes的脂质分化模型中评估SDAR的疗效,测量活性氧物种 (ROS),炎症标记物和CCAAT/增强剂结合蛋白β (C/EBPβ) 活性.

主要成果:

SDAR水凝表现出稳定的光热性能 (~44°C),高生物相容性,93.7%的抗氧化剂率和显著的抗炎性质.
在脂质分化模型中,SDAR治疗使细胞内ROS和炎症标志物减少了50%以上.
通过减弱C/EBPβ结合活性,SDAR有效抑制了脂原分化.

结论:

对光热反应的SDAR水凝是一种有前途的生理化疗策略,用于治疗肥胖症.
SDAR有效地抑制脂质生成,并减少与肥胖相关的关键细胞标记物.
这项研究突出了工程纳米复合物水凝在解决肥胖等代谢障碍方面的潜力.

关键词:

抗氧化和抗炎的水凝具有抗氧化和抗炎作用.抑制脂肪生成的抑制.物理化学疗法物理化学疗法这是一种Resveratrol纳米颗粒.转录基因组测序分析分析

更多相关视频

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Published on: June 2, 2015

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...